



#10/c
BP
Response under 37 CFR 1.116 5-15-03
Expedited Procedure (NE)
Examining Group 1631

Attorney Docket No. 5849.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Berka *et al.*

Confirmation No. 6980

Serial No.: 09/533,559

Group Art Unit: 1631

Filed: March 22, 2000

Examiner: J.S. Brusca

For: Methods For Monitoring Multiple Gene Expression

AMENDMENT

RECEIVED

MAY 15 2003

Commissioner for Patents
Washington, DC 20231

TECH CENTER 1600/2900

Sir:

In response to the Office Action dated November 7, 2002, please amend the above-captioned application as follows:

IN THE CLAIMS

Please cancel claims 90-102 without prejudice or disclaimer. Please add new claims 103-110. The following is the status of the claims of the above-captioned application, as amended.

Claims 90-102 cancelled.

103. (New) A method for monitoring differential expression of a plurality of genes in a first filamentous fungal cell relative to expression of the same genes in one or more second filamentous fungal cells, comprising:

(a) adding a mixture of fluorescence-labeled nucleic acids isolated from the filamentous fungal cells to a substrate containing an array of *Aspergillus oryzae* ESTs selected from the group consisting of SEQ ID NOs. 4377-7401 and fragments thereof, under conditions where the nucleic acids hybridize to complementary sequences of the ESTs in the array, wherein the nucleic acids from the first filamentous fungal cell are labeled with a first fluorescent reporter and the one or more



Attorney Docket No.: 5849.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Berka et al.

Confirmation No: Berka et al.

Serial No.: 09/533,559

Group Art Unit: To be assigned

Filed: March 22, 2000

Examiner: To be assigned

For: Methods For Monitoring Multiple Gene Expression

AMENDMENT FEE TRANSMITTAL

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED

MAY 15 2003

TECH CENTER 1600/2900

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed **November 7, 2002**.

It is respectfully requested that the time for response to the Office Action be extended for a period of **3 months** from **February 8, 2003** to **May 7, 2003**. The required fee for the extension is estimated to be **\$930.00**.

The fee for claims has been calculated as shown below:

No additional claims fee is required.

Please charge the required extension and claims fees, estimated to be **\$930.00**, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: May 7, 2003

Robert L. Starnes, Reg. No. 41,324
Novozymes Biotech, Inc.
1445 Drew Avenue
Davis, CA 95616
(530) 757-8100